Announcement • Aug 14

Eupraxia Pharmaceuticals Reports Symptom Response Data From Ongoing Phase 1b/2a RESOLVE Trial Including New Data On Odynophagia In Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals Inc. announced positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the effect of EP-104GI on odynophagia (pain when swallowing). The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment. In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints. The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment. At baseline 31% of patients in Cohorts 7-9 had severe dysphagia; no patients had severe dysphagia at 24 and 52 weeks post treatment. EP-104GI continues to be well tolerated by patients receiving the drug. There have been over 130 patients treated in RESOLVE with EP-104GI or placebo (more than 2,000 individual injection sites) with no reported treatment-emergent or procedure related Serious Adverse Events (“SAEs”). Patients in the RESOLVE trial were asked to grade the degree of odynophagia (pain whilst swallowing) on an 11-point scale (0 = no pain, 10 = most severe pain) over the seven previous days. Measurements were recorded at baseline and at weeks 2, 4, 8, 12, 24, 36 and 52 following dosing with EP-104GI. Symptom severity was graded as most severe (score of 10), severe (scores of 7-9), moderate (scores of 4-6), mild (scores of 1-3) or none (score of 0). An analysis of the distribution of severity of symptom score was performed for the patients that received 20 injections of EP-104GI (Cohorts 7 to 9, receiving a total dose ranging from 80 mg to 160 mg in 20 injections). At baseline 62% of the EoE patients reported either moderate or severe odynophagia (n=13). At 2, 4, 8 and 12 weeks post treatment, 31% of patients reported moderate or severe odynophagia (n=13). At 24, 36 and 52 weeks, 25% of patients reported moderate or severe odynophagia (n = 12,12 and 8 respectively). At baseline, 15% of patients recorded no odynophagia, at 52 weeks, 50% of patients recorded no odynophagia. Patients in the RESOLVE trial were asked to grade the degree of dysphagia (difficulty swallowing) on an 11-point scale (0 = no troubles to swallow, 10 = most severe troubles to swallow) over the seven previous days. Measurements were recorded at baseline and at weeks 2, 4, 8, 12, 24, 36 and 52 following dosing with EP-104GI. Symptom severity was graded as most severe (score of 10), severe (scores of 7-9), moderate (scores of 4-6), mild (scores of 1-3) or none (score of 0). An analysis of the distribution of severity of symptom score was performed for the patients that received 20 injections of EP-104GI (Cohorts 7-9, receiving a total dose ranging from 80 mg to 160 mg). At baseline 77% of the EoE patients reported moderate or severe dysphagia (n=13). At 12 weeks post treatment, 54% of patients reported moderate or severe dysphagia (n=13). At 24 and 52 weeks, only 25% of patients reported moderate or severe dysphagia (n = 12 and 8 respectively). The Phase 1b/2a part of the RESOLVE trial is a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with a history of confirmed active EoE. The treatment is administered as a single dose via 4 to 20 esophageal wall injections, with dose escalations modifying either the dose per site and/or the number of sites. Patients were followed for up to 24 weeks in Cohorts 1-4 (4x1mg, 8x1mg, 8x2.5mg and 12x2.5mg) or 52 weeks in Cohorts 5-9 (12x4mg, 16x4mg, 20x4mg, 20x6mg and 20x8mg). Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in the coming months. The Phase 2b part of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting both the 120mg (20x6mg) and 160mg (20x8mg) doses. The interim data from the Phase 2b part of the RESOLVE trial is expected in Fourth Quarter 2026.

Eupraxia Pharmaceuticals Inc. Stock Price

EPRX Share Price Performance

EPRX Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Eupraxia Pharmaceuticals Inc. Key Details

About EPRX

Recent EPRX News & Updates

Independent Director recently bought CA$207k worth of stock

Eupraxia Pharmaceuticals Reports Symptom Response Data From Ongoing Phase 1b/2a RESOLVE Trial Including New Data On Odynophagia In Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals Inc. Announces Executive Changes

Recent updates

Eupraxia Pharmaceuticals Inc. Competitors

Curaleaf Holdings

Green Thumb Industries

Cronos Group

Knight Therapeutics